Abstract
Hepatic encephalopathy is a complex neuropsychiatric syndrome that may complicate either chronic or acute liver failure. Hepatic encephalopathy associated with fulminant liver failure is characterised by the development of cerebral oedema and intracranial hypertension, and has a poor outcome in severe cases if liver transplantation is not performed. Medical management of hepatic encephalopathy in fulminant liver failure is essentially directed toward the prevention and treatment of cerebral oedema and intracranial hypertension. Mannitol infusion should remain the main pharmacological treatment of cerebral oedema. Despite a lack of randomised clinical trial data, thiopental (thiopentone) has been widely accepted as an effective means of treating intracranial hypertension when mannitol fails. Acetylcysteine seems to have a beneficial effect by improving the cerebral blood flow and the cerebral metabolic rate for oxygen. The effectiveness of lactulose is well established in chronic hepatic encephalopathy but not in fulminant liver failure. As the precise pathogenesis of hepatic encephalopathy in patients with fulminant liver failure is unknown, there is no specific treatment of this syndrome. In spite of a large number of published articles on the treatment of hepatic encephalopathy, only a few randomised, controlled studies are available. Indeed, except for the rare cases in which treatment of the underlying cause of disease is possible, the treatment of patients with fulminant liver failure is currently emergency liver transplantation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997; 92: 1429–39
Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473–9
Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996; 16: 329–38
Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995; 345: 163–9
Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862–72
Sussman NL, Lake JR. Treatment of hepatic failure — 1996: current concepts and progress toward liver dialysis. Am J Kidney Dis 1996; 27: 605–21
Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16: 379–88
Ferenci P. Pathophysiology of hepatic encephalopathy. Hepatogastroenterology 1991; 38: 371–6
Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Proc Soc Exp Biol Med 1994; 206: 329–44
Blei AT. Cerebral oedema and intracranial hypertension in acute liver failure: distinct aspects of the same problem. Hepatology 1991; 13: 376–9
Sussman NL. Fulminant hepatic failure. In: Lee WM, Williams R, editors. Acute liver failure. Cambridge (UK): Cambridge University Press, 1997: 618–50
Hahn M, Massen O, Neucki R, et al. Die Ecksche fistel zwishen der unteren hahlvene und der pfortanden und folgen für den Organismus. Arch Exp Pathol Pharmakol 1893; 32: 162–210
Record CO, Buxton B, Chase RA, et al. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 1976; 6: 387–94
Bergeron M, Layrargues GP, Butterworth RF. Aromatic and branched-chain amino-acids in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Metab Brain Dis 1989; 4: 169–76
Michalack A, Butterworth RF. Selective increases of extracellular brain concentrations of aromatic and branched-chain amino-acids in relation to deterioration of neurological status in acute (ischaemic) liver failure. Metab Brain Dis 1997; 12: 259–69
Butterworth RF, Giguere J-F, Michaud J, et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1–12
Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Lancet 1982; I: 18–20
Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25: 1303–5
Basile AS, Hughes RD, Harrisson PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991; 325: 473–8
Potvin M, Finlayson MH, Hinchey EJ, et al. Cerebral abnormalities in hepatectomized rats with acute hepatic coma. Lab Invest 1984; 50: 560–4
Trabers PG, DelCanto M, Ganger DR, et al. Electron microscopic evaluation on brain oedema in rabbits with galactosamine-induced fulminant hepatic failure: ultrastructure and integrity of the blood brain-barrier. Hepatology 1997; 7: 1272–7
Norenberg MD. Astrocyte responses to CNS injury. J Neuropathol Exp Neurol 1994; 53: 213–20
Swain MS, Blei AT, Butterworth RF, et al. Intracellular pH rises and astrocytes swell after portocaval anastomosis in rats. Am J Physiol 1991; 261: R1491–6
Seda HMW, Hughes RD, Gove CD, et al. Inhibition of rat Na+-K+ ATPase activity by serum from patients with fulminant hepatic failure. Hepatology 1984; 4: 74–9
Ede RJ, Gove CD, Hughes RD, et al. Reduced brain Na+-K+ ATPase activity in rats with galactosamine-induced hepatic failure: relationship to encephalopathy and cerebral oedema. Clin Sci 1987; 72: 365–71
Yang SS, Hughes RD, Williams R. Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose. Hepatology 1998; 8: 93–7
Pappas SC, Ferenci P, Jones EA. Evidence againts the hypothesis that cerebral oedema in fulminant hepatic failure is due to decreased neural Na+-K+ ATPase activity [abstract]. Hepatology 1983; 3: 848
Martinez-Hernandez A, Bell KP, Norenberg MD. Glutamine synthetase: glial localisation in brain. Science 1977; 195: 1356–85
Swain MS, Butterworth RF, Blei AT. Ammonia and related amino acids in the pathogenesis of brain oedema in acute ischaemic liver failure in rats. Hepatology 1992; 15: 449–53
Record CO, Buxton B, Chase RA, et al. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 1976; 6: 387–94
McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995; 333: 1260–6
McConnell JR, Antonson DL, Ong CS et al. Proton spectroscopy of brain amino acid and putative neuro-transmitter alterations during acute hepatic coma in rat. Hepatology 1995; 22: 69–74
Seery JP, Taylor-Robinson SD. The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. J Hepatol 1996; 25: 988–98
Geissler A, Lock G, Frund R, et al. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997; 25: 48–54
Albrecht J, Bender AS, Nuremberg MD. Ammonia stimulates the release of taurine from cultured astrocytes. Brain Res 1994; 660: 282–92
Häussinger D, Laubenberger J, von Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypoosmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475–80
Laubenberger J, Häussinger D, Boyer S, et al. Proton magnetic resonance spectroscopy of brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112: 161–6
Norenberg MD, Bender AS. Astrocyte swelling in liver failure. Role of glutamine and benzodiazepines. Acta Neurochir 1994; 60 Suppl.: 24–7
Treem WR. Inherited and acquired syndromes of hyperammonemia and encephalopathy in children. Semin Liver Dis 1994; 14: 236–58
Watson AJ, Chambers T, Karps JE, et al. Transient idiopathic hyperammoniemia in adults. Lancet 1985; 328: 1271–4
Takahashi H, Koehler RC, Brusilow SW, et al. Inhibition of brain glutamine accumulation prevents cerebral oedema in hyperammoniemic rats. Am J Physiol 1991; 261: G825–9
Voorheis TM, Ehrlich ME, Duffy TE, et al. Acute hyperammonemia in the young primate: physiologic and neuropathologic correlates. Paediatr Res 1983; 17: 970–5
Blei AT, Olafsson S, Therrien G, et al. Ammonia-induced brain oedema and intracranial hypertension in rats after portacaval anastomosis. Hepatology 1994; 19: 1431–44
Wendon JA, Harrisson PM, Keays R, et al. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19: 1407–13
Shah V, Webster S, Gottstein J, et al. Reduction of cerebral perfusion precedes the rise of intracranial pressure in rats with ischaemic fulminant liver failure. Hepatology 1993; 17: 1117–21
Larsen FS, Ejlersen E, Hansen BA, et al. Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol 1995; 23: 212–7
Larsen FS, Ejlersen E, Clemmesen JO, et al. Preservation of cerebral oxidative metabolism in fulminant hepatic failure: an autoregulation study. Liver Transpl Surg 1996; 2: 348–53
Strauss G, Hansen BA, Kirkegaard P, et al. Liver function, cerebral blood flow autoregulation, and hepatic encephalopathy in fulminant hepatic failure. Hepatology 1997; 25: 837–9
Larsen FS, Hansen BA, Pott F, et al. Dissociated cerebral vasoparalysis in acute liver failure: a hypothesis of gradual cerebral hyperemia. J Hepatol 1996; 25: 145–51
Durham S, Yonas H, Aggarwal S, et al. Regional blood flow and CO2 reactivity in fulminant hepatic failure. J Cereb Blood Flow Metab 1995; 15: 329–35
Strauss G, Hansen BA, Knudsen GM, et al. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol 1998; 28: 199–203
Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990; 11: 49–53
Rolando N, Harvey F, Brahm J, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12: 1–9
Rolando N, Philpott-Howard J, Williams R. Management of infection in acute liver failure. In: Lee WM, Williams R, editors. Acute liver failure. Cambridge (UK): Cambridge University Press, 1997: 158–71
Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enterai antimicrobial regimen in fulminant liver failure. Hepatology 1993; 17: 196–201
Rolando N, Wade JJ, Stangon A, et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enterai decontamination, in patients with acute liver failure. Liver Transpl Surg 1996; 2: 8–13
Elkington F, Floch MH, Conn HO. Lactulose in the treatment of portal-systemic encephalopathy: a double-blind clinical trial. N Engl J Med 1969; 281: 408–12
Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970; 59: 827–32
Germain L, Frexinos J, Louis A, et al. Etude en double aveugle du lactulose chez 18 malades atteints d’encéphalopathie hépatique chronique après shunt portocave. Arch Fr Mal App Dig 1973; 62: 293–301
Blanc P, Daures JP, Liantard J, et al. Association lactulose-neomycine versus placebo dans le traitement de l’encéphalopathie hépatique aiguë: resultats d’un essai controlé randomisé. Gastroenterol Clin Biol 1994; 18: 1063–8
Conn HO, Leevy CM, Vlahvevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double-blind controlled trial. Gastroenterology 1977; 72: 573–83
Blanc P, Daures JP, Rouillon JM et al. Lacticol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992; 15: 222–8
Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lacticol and lactulose) vs nonacidifying enemas (tap water) to treat acute portal—systemic encephalopathy: a double-blind, randomised clinical trial. Hepatology 1987; 7: 639–43
Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398–406
Morgan MH, Read AE, Speller DCE. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23: 1–7
Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109–18
Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomised trial. Hepatology 1992; 16: 138–44
Liehr H, Huth M, Kircheis G, et al. A comparison of L-ornithine-L-aspartate and lactulose in the management of chronic liver disease and hepatic encephalopathy [abstract]. J Gastroenterol 1992; 7: A106
Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis: a double-blind, randomised study using a four-fold crossover design. J Hepatol 1993; 19: 424–30
Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351–60
Munoz SJ. Nutritional therapies in liver disease. Semin Liver Dis 1991; 11:278–81
Morgan MY. Branched chain amino acids in the management of chronic liver disease: facts and fantasies. J Hepatol 1990; 11: 133–41
Eriksson LSE, Conn HO. Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology 1989; 10: 1228–46
Naylor CD, O’Rourke K, Detsky AS, et al. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. Gastroenterology 1989; 97: 1033–42
Ferenci P. Pathophysiology of hepatic encephalopathy. Hepatogastroenterology 1991; 38: 371–6
Baraldi M, Zeneroli. Experimental hepatic encephalopathy: changes in the binding of gamma-amino-butyric acid. Science 1992; 216: 427–33
Bosnian DK, Van den Buijs CA, de Haan JG, et al. The effects of benzodiazepine-receptors antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. Gastroenterology 1991; 101: 772–80
Steindl P, Püspok A, Druml W, et al. Beneficial effect of pharmacological modulation of the GABAa-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991; 14: 963–8
van der Rijt CC, De Knegt RJ, Schalm SW, et al. Flumazenil does not improve hepatic encephalopathy associated with acute ischaemic liver failure in the rabbit. Metab Brain Dis 1990; 5: 131–41
Bansky G, Meier PJ, Riederer E, et al. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989; 97: 744–50
Gyr K, Meier R. Flumazenil in the treatment of portal systemic encephalopathy — an overview. Intensive Care Med 1991; 17: S39–42
van der Rijt CCD, Schalm SW, Meulstee J, et al. Flumazenil therapy for hepatic encephalopathy: a double-blind cross-over study [abstract]. Hepatology 1989; 10: 590
Cadranel JF, El Younsi M, Pidoux B, et al. Immediate improvement of hepatic encephalopathy in cirrhotic patients by flumazenil: results of a double-blind cross-over study [abstract]. J Hepatol 1991; 13:S104
Meier R, Gyr K, Häussier R, et al. Treatment of portosystemic encephalopathy with the benzodiazepine-receptor antagonist flumazenil: a randomised, double-blind, placebo-controlled, multicenter study [abstract]. Gastroenterology 1994; 106: A942
Pomier-Layrargues G, Giguère JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomised double-blind placebo-controlled crossover trial. Hepatology 1994; 19: 32–7
Cadranel JF, El Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomised, placebo study. Eur J Gastroenterol Hepatol 1995; 7: 325–9
van der Rijt CCD, Schalm SW, Meulstee J, et al. Flumazenil therapy for hepatic encephalopathy. Gastroenterol Clin Biol 1995; 19: 572–80
Groeneweg M, Gyr K, Amrein R, et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy: results of a double-blind, randomised, placebo-controlled multicenter trial. Electroencephalogr Clin Neurophysiol 1996; 98: 29–34
Gyr K, Meier R, Häussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicenter study. Gut 1996: 39: 319–24
Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985; I: 1324–5
Grimm G, Katzenschlager R, Schneeweiss B, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; II: 1392–4
Sutherland LR, Minuk GY. Ro 15-1788 and hepatic failure [abstract]. Ann Intern Med 1988; 108: 158
Devictor D, Tahiri C, Lanchier C, et al. Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure. Intensive Care Med 1995; 21: 253–6
Herrine SK, Northrup B, Bell R, et al. The effect of head elevation on cerebral perfusion in fulminant hepatic failure [abstract]. Hepatology 1995; 22: 289A
Davenport A, Will EJ, Davison AM. Effect of posture on intracranial pressure and cerebral perfusion pressure in patients with fulminant hepatic and renal failure after acetaminophen self-poisoning. Crit Care Med 1990; 18: 286–9
Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572–3
Harrison PM, Wendon JA, Gimson AES, et al. Improvement by acetylcysteine of hemodynamic and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852–7
Blei AT, Olafsson S, Webster S, et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341: 157–8
Munoz SJ, Robinson M, Northrup B, et al. Elevated intracranial pressure and computed tomography of the brain in fulminant hepatocellular failure. Hepatology 1990; 13: 209–12
Keays TR, Alexander GJM, Williams R. The safety and the value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993; 18: 205–9
Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992; 16: 1–7
Ede R, Gimson AES, Bihari D, et al. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986; 2: 43–51
Canalese J, Gimson AES, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982; 23: 625–9
Pierce EC, Lambstein CJ, Deutsch S, et al. Cerebral circulation and metabolism during thiopental anesthesia and hyperventilation in man. J Clin Invest 1962; 41: 1664–71
Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1988; 69: 15–23
Schwartz ML, Tator CH, Rowed DW, et al. The University of Toronto head injury treatment study: a prospective randomised comparison of pentobarbital and mannitol. Can J Neurol Sci 1984; 11:434–40
Ward JD, Becker DP, Miller JD, et al. Failure of prophylactic barbiturate coma in the treatment of severe head injury. J Neurosurg 1984; 62: 383–8
Forbes A, Alexander GJM, O’Grady JG, et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 1989; 10: 306–10
Davies MH, Mutimer D, Lowes J, et al. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet 1994; 343: 1329–30
Munoz SJ, Moritz MJ, Martin P, et al. Relationship between cerebral perfusion pressure and systemic hemodynamics in fulminant hepatic failure [abstract]. Transplant Proc 1993; 25: 1776
Gimson AES, Braude S, Mellon PJ, et al. Earlier charcoal hemoperfusion in fulminant hepatic failure. Lancet 1982; 2: 681–3
O’Grady JG, Gimson AES, O’Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186–92
Bihari D, Hughes RD, Gimson AES, et al. Effect of serial resin hemoperfusion in fulminant hepatic failure. Int J Artif Organs 1983; 6: 299–302
Silk DBA, Trewby PN, Chase RA, et al. Treatment of fulminant hepatic failure by polyacrylonitrile membrane hemodialysis. Lancet 1977; II: 1–3
Redeker AG, Yamahiro HS. Controlled trial of exchange transfusion therapy in fulminant hepatitis. Lancet 1973; II: 3–6
Cooper GN, Karlson KE, Clowes GHA, et al. Total body washout and exchange: a valuable tool in acute hepatic coma and Reye’s syndrome. Am J Surg 1977; 133: 522–30
Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21: 328–38
Fox IJ, Langnas AN, Ozaki CF, et al. Successful application of extracorporeal liver perfusion for the treatment of fulminant hepatic failure; a technology whose time has come. Am J Gastroenterol 1993; 88: 1876–81
Chari RS, Collins BH, Magee JC, et al. Brief report: treatment of hepatic failure with ex vivo pig liver perfusion followed by liver transplantation. N Engl J Med 1994; 331: 234–7
Matsumura KN, Guevara GR, Houston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987; 101: 99–103
Saito S, Sakagami K, Orita K. Anew hybrid artificial liver using a combination of hepatocytes and biomatrix. Trans Am Society Artif Organs 1987; 33: 459–62
Sussman NL, Chong MG, Koussayir T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16: 60–5
Neuzil DF, Rozga J, Moscioni AD, et al. Use of anovel bioartificial liver in a patient with acute liver insufficiency. Surgery 1993; 113: 340–3
Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fibre module inoculated with liver cells. Hepatology 1993; 17: 256–65
Demetriou AA, Rozga J, Podesta L, et al. Early clinical experience with a bioartificial liver. Scand J Gastroenterol 1995; 30: 111–7
Watanabe FD, Mullon C, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial. Ann Surg 1997; 225: 484–94
Benhamou JP, Rueff B, Sico C. Severe hepatic failure: a critical study of current therapy. In: Orlandi F, Jezequel AM, editors. Liver and drugs. New York: Academic Press, 1972: 213–28
Gubernatis G, Pichmayr R, Kemnitz J, et al. Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure: the first successful case report. World J Surg 1991; 15: 660–5
Boudjema K, Cherqui D, Jaeck D, et al. Auxiliary liver transplantation for fulminant and subfulminant hepatic failure. Transplantation 1995; 59: 218–23
Chenard-Neu MP, Boudjema K, Bernuau J, et al. Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure: a multicenter European study. Hepatology 1996; 23: 1119–27
Bismuth H, Azoulay D, Samuel D, et al. Auxiliary partial orthotopic liver transplantation for fulminant hepatitis. Ann Surg 1997; 224: 712–26
Pereira SP, McCarthy M, Ellis AJ, et al. Auxiliary partial orthotopic liver transplantation. J Hepatol 1997; 26: 1010–7
Sudan DL, Shaw BW, Fox IJ, et al. Long term follow-up of auxiliary orthotopic liver transplantation for the treatment of fulminant hepatic failure. Surgery 1997; 122: 771–8
Ringe B, Lubbe N, Kuse E, et al. Management of emergencies before and after liver transplantation by early total hepatectomy [abstract]. Transplant Proc 1993; 235: 1090
Rozga J, Pobesta L, LePage E, et al. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993; 342: 898–9
So SKS, Barteau GA, Perdrizet GA, et al. Successful retransplantation after a 48-hour anhepatic state. Transplant Proc 1993; 25: 1962–3
Lee WM. Total hepatectomy for acute liver failure: don’t take out my liver! Gastroenterology 1994; 107: 894–7
Bernuau J, Samuel D, Durand F, et al. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study [abstract]. Hepatology 1991; 14: 49A
O’Grady JG, Alexander GJM, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 4439–45
Takahashi Y, Kumada H, Shimizu M, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19: 1065–71
Debray D, Cullufi P, Devictor D, et al. Liver failure in children with hepatitis A. Hepatology 1997; 26: 1018–22
Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997; 26: 62–8
Devlin J, Wendon J, Heaton N, et al. Pretransplantation clinical status and outcome of emergency transplantation for acute liver failure. Hepatology 1995; 21: 1018–24
Pauwels A, Mostefa-Kara N, Florent C, et al. Emergency liver transplantation for acute liver failure: evaluation of London and Clichy criteria. J Hepatol 1993; 17: 124–7
Van Thiel DH, When should a decision to proceed with transplantation actually be made in cases of fulminant or subfulminant hepatic failure: at admission to hospital or when a donor organ is made available? J Hepatol 1993; 17: 1–2
Vickers C, Neuberger J, Buckels J, et al. Transplantation of the liver in adults and children with fulminant hepatic failure. J Hepatol 1988; 7: 143–50
Emond JC, Aran PP, Whitington PF, et al. Liver transplantation in the management of fulminant hepatic failure. Gastroenterology 1989; 96: 1583–8
Williams R, O’Grady JG. Liver transplantation: results, advances and problems. J Gastroenterol Hepatol 1990; 5: 110–26
Ascher N, Lake JR, Emond JC, et al. Liver transplantation for fulminant hepatic failure. Arch Surg 1993; 128: 677–82
Moreno Gonzalez F, Loinaz C, Gascia I, et al. Orthotopic liver transplantation in 35 patients with fulminant hepatic failure. Transplant Proc 1994; 26: 3640–1
Dodson SF, Dehara K, Iwatsuki S. Liver transplantation for fulminant hepatic failure. ASAIO J 1994; 40: 86–8
Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis: the Paul Brousse experience. Ann Surg 1995; 222: 109–19
Devictor D, Desplanques L, Debray D, et al. Emergency liver transplantation for fulminant liver failure in infants and children. Hepatology 1992; 16: 1156–62
Tan KC, Mondragon RS, Vougas V, et al. Liver transplantation for fulminant hepatic failure and late-onset hepatic failure in children. Br J Surg 1992; 79: 1192–4
Dawan A, Langnas AN, Vanderhoof JA, et al. Outcome of liver transplantation for fulminant liver failure in children: 10 year experience [abstract]. Hepatology 1995; 22: 208A
Bhaduri BR, Mieli-Vergani G. Fulminant hepatic failure: paediatric aspects. Semin Liver Dis 1996; 16: 349–55
Rivera-Penera T, Moreno J, Skaff C, et al. Delayed encephalopathy in fulminant hepatic failure in the paediatric population and the role of liver transplantation. J Pediatr Gastroenterol Nutr 1997; 24: 128–34
Bonatti H, Muiesan P, Connolly S, et al. Liver transplantation for acute liver failure in children under 1 year of age. Transplant Proc 1997; 29: 434–5
Tissières P, Debray D, Soubrane, et al. Liver transplantation for fulminant liver failure in infancy and childhood [abstract]. Ped Transpl 1998; 2: 53
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tissières, P., Devictor, D. Drug Treatment of Encephalopathy Associated with Fulminant Liver Failure. Mol Diag Ther 11, 335–349 (1999). https://doi.org/10.2165/00023210-199911050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199911050-00002